These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31531807)

  • 1. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.
    Maghrabi HME; Elmowafy AY; Refaie AF; Elbasiony MA; Shiha GE; Rostaing L; Bakr MA
    Int Urol Nephrol; 2019 Dec; 51(12):2295-2304. PubMed ID: 31531807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
    Saxena V; Khungar V; Verna EC; Levitsky J; Brown RS; Hassan MA; Sulkowski MS; O'Leary JG; Koraishy F; Galati JS; Kuo AA; Vainorius M; Akushevich L; Nelson DR; Fried MW; Terrault N; Reddy KR
    Hepatology; 2017 Oct; 66(4):1090-1101. PubMed ID: 28504842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China.
    Zhang J; Sun W; Lin J; Tian Y; Ma L; Zhang L; Zhu Y; Qiu W
    BMC Infect Dis; 2019 Jul; 19(1):645. PubMed ID: 31324230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.
    Elmowafy AY; El Maghrabi HM; Mashaly ME; Eldahshan KF; Rostaing L; Bakr MA
    Int Urol Nephrol; 2019 Dec; 51(12):2243-2254. PubMed ID: 31612423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Chronic Hepatitis C Infection Among Egyptian Kidney Transplant Recipients: A Pilot Study.
    El Maghrabi HM; Elmowafy AY; Donia AF; Ismail MI; El-Hendy YA; Soliman R; Shiha GE; Bakr MA
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):62-67. PubMed ID: 30777525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis.
    Saab S; A Jimenez M; N Bau S; Choi G; Durazo FA; M El-Kabany M; Han SB; Busuttil RW
    J Clin Gastroenterol; 2017 Feb; 51(2):167-173. PubMed ID: 27548734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
    Chute DF; Chung RT; Sise ME
    Kidney Int; 2018 Mar; 93(3):560-567. PubMed ID: 29325996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel antiviral agents for the treatment of HCV among renal transplant recipients].
    Fabrizi F; Donato FM; Messa P
    G Ital Nefrol; 2017 Aug; 34(4):35-50. PubMed ID: 28762681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
    Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
    Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.
    Ibrahim Mohammed Ebid AH; Ashraf Ahmed O; Hassan Agwa S; Mohamed Abdel-Motaleb S; Mohamed Elsawy A; Hagag RS
    J Clin Pharm Ther; 2020 Jun; 45(3):539-546. PubMed ID: 31889322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
    Alkadi MM; Abuhelaiqa EA; Elshirbeny MF; Hamdi AF; Fituri OM; Asim M; Alkaabi SR; Derbala MF; Jarman ME; Ashour AM; Nauman A; Al Maslamani YK; Butt AA; Al-Malki HA
    Immun Inflamm Dis; 2021 Mar; 9(1):246-254. PubMed ID: 33264509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease.
    Elmowafy AY; Abbas MH; Denewar AA; Mashaly ME; Shiha G; El Wasif SM; Rostaing L; Bakr MA
    Int Urol Nephrol; 2021 Apr; 53(4):749-761. PubMed ID: 33111161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era.
    Devresse A; Delire B; Lazarus JV; Kabamba B; De Meyer M; Mourad M; Buemi A; Darius T; Cambier JF; Goffin E; Jadoul M; Kanaan N
    Transplant Proc; 2020 Apr; 52(3):815-822. PubMed ID: 32143864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
    Kamar N; Marion O; Rostaing L; Cointault O; Ribes D; Lavayssière L; Esposito L; Del Bello A; Métivier S; Barange K; Izopet J; Alric L
    Am J Transplant; 2016 May; 16(5):1474-9. PubMed ID: 26587971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
    J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
    Chevallier E; Büchler M; Caillard S; Bouvier N; Colosio C; Rivalan J; Sayegh J; Bertrand D; Le Meur Y; Thierry A; Garrouste C; Rerolle JP; Rostaing L; Gatault P
    Transplant Proc; 2020 Dec; 52(10):3179-3185. PubMed ID: 32636068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.